Verifying…
Home / Drug A–Z / Neo Presol Lotion_

Neo Presol Lotion_

NAFDAC Reg. No. 04-2017 · Drug

Registered with NAFDAC. Registration activeAs of 27 October 2026 · synced automatically from official sources.
Product
Neo Presol Lotion_
NAFDAC number
04-2017
Active ingredient
Methylprednisolone Acetate; Neomycin Sulfate
Strength
2.5 mg; 2.5 mg
Form
Lotion
Pack size
1 x 25 mL (in plastic bottle)
Manufacturer
Not listed
Applicant (holder)
Drugfield Pharmaceuticals Limited
Approved
24 Sep 2025
Status
Active View on NAFDAC ↗
Registration valid to
23 Sep 2030
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Neo Presol Lotion_ is on the NAFDAC register with an active registration (04-2017). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

What Neo Presol Lotion_ is used for

From the official U.S. FDA label for methylprednisolone acetate, the active ingredient registered with NAFDAC.

What it is used for

A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. …

Possible side effects

The following adverse reactions have been reported with methylprednisolone acetate or other corticosteroids: Allergic reactions : Allergic or hypersensitivity reactions, anaphylactoid reaction, anaphylaxis, angioedema. Blood and lymphatic system disorders: Leukocytosis. Cardiovascular : Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see WARNINGS ), pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis. …

Do not use if

Methylprednisolone acetate injectable suspension is contraindicated in patients with known hypersensitivity to the product and its constituents. Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. Methylprednisolone acetate injectable suspension is contraindicated for intrathecal administration. This formulation of methylprednisolone acetate has been associated with reports of severe medical events when administered by this route. …

Warnings

Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use. General This product is not suitable for multi-dose use. …

Pregnancy & breastfeeding

Pregnancy: Teratogenic Effects Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring. There are no adequate and well-controlled studies in pregnant women. …

General information only, not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Neo Presol Lotion_

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Neo Presol Lotion_

What is in Neo Presol Lotion_?

Neo Presol Lotion_ contains Methylprednisolone Acetate; Neomycin Sulfate (2.5 mg; 2.5 mg), as lotion, according to its NAFDAC registration record.

Is Neo Presol Lotion_ registered with NAFDAC?

Yes. Neo Presol Lotion_ is listed on the NAFDAC register under registration number 04-2017, and its registration is active as of 27 October 2026.

Has Neo Presol Lotion_ been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Neo Presol Lotion_ in our automatically synced alert list.

How can I check that my pack of Neo Presol Lotion_ is genuine?

Run a free authenticity scan with the NAFDAC number 04-2017, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Neo Presol Lotion_ used for?

A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequ (Summarised from the official U.S. FDA label for methylprednisolone acetate. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Neo Presol Lotion_? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.